NCT06111547

A Study of TAK-279 in Healthy Chinese Adults

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Oral Doses Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of TAK-279 in Healthy Chinese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The main aim of this study is to find out how the body of a healthy Chinese adult processes TAK-279 (pharmacokinetics). Other aims are to learn about side effects and how well TAK-279 is tolerated when given to healthy Chinese Adults. Participants will receive either TAK-279 or a placebo on Day 1 and from Day 6 to Day 19. Blood samples will be taken at different timepoints throughout the study participation. Participants will need to adhere to certain lifestyle restrictions during the study. This also includes eating and drinking restrictions. During the study, participants will need to stay at the clinic for 25 days.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	TAK-279	TAK-279 oral tablet.
DRUG	Placebo	TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.

Timeline

• Start date: 2024-06-24
• Primary completion: 2024-07-23
• Completion: 2024-08-04
• First posted: 2023-11-01
• Last updated: 2024-08-07

Locations

1 site across 1 country: China